Scarica l'app Stockscreener
2.151
5.68%
0.121
Precedente Chiudi:
$2.03
Aprire:
$2.02
Volume 24 ore:
111.77K
Relative Volume:
0.08
Capitalizzazione di mercato:
$134.85M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-1.2084
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
+16.60%
1M Prestazione:
-12.43%
6M Prestazione:
+130.69%
1 anno Prestazione:
+89.86%
Intervallo 1D:
$1.99
$2.17
Intervallo di 1 settimana:
$1.81
$2.30
Portata 52W:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
2.145 | 127.62M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.77 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.30 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.84 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.09 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.08 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Hedge Fund Bets: Will Prelude Therapeutics Incorporated announce a stock splitJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology - TipRanks
Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last week - Yahoo Finance
Aug Highlights: Does MAMO outperform in volatile markets2025 Support & Resistance & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Aug Reactions: Can Prelude Therapeutics Incorporated outperform under higher oil pricesQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Review: Is Prelude Therapeutics Incorporated a cyclical or defensive stockMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
How Prelude Therapeutics Incorporated stock compares to industry benchmarksPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
How Prelude Therapeutics Incorporated stock responds to policy changesMarket Activity Recap & Fast Entry High Yield Stock Tips - ulpravda.ru
Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prelude Therapeutics Inc Announces New Clinical Developments - TradingView — Track All Markets
Aug Sentiment: How Prelude Therapeutics Incorporated stock responds to policy changesWeekly Investment Summary & Real-Time Market Sentiment Alerts - Улправда
Will Prelude Therapeutics Incorporated stock reach all time highs in 2025Portfolio Update Report & Expert Verified Movement Alerts - Улправда
Will Prelude Therapeutics Incorporated stock benefit from AI adoptionJuly 2025 Rallies & Free Real-Time Market Sentiment Alerts - Улправда
Quarterly Trades: Is Prelude Therapeutics Incorporated stock positioned well for digital economyStop Loss & Free Daily Entry Point Trade Alerts - ulpravda.ru
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December - MarketBeat
Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US$2.75m - Sahm
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1%What's Next? - MarketBeat
Is Prelude Therapeutics Stock Built to Withstand a Pullback? - Trefis
What dividend safety score for Prelude Therapeutics Incorporated stock2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
Risk Analysis: What technical signals suggest for Prelude Therapeutics Incorporated stockForecast Cut & High Yield Stock Recommendations - Улправда
Is Prelude Therapeutics Incorporated stock a buy before product launches2025 Price Action Summary & Technical Pattern Based Signals - Улправда
Trend Report: Can Prelude Therapeutics Incorporated stock resist market sell offsJuly 2025 Setups & Free High Return Stock Watch Alerts - Улправда
Is Prelude Therapeutics Incorporated stock positioned well for digital economyPrice Action & Technical Confirmation Alerts - DonanımHaber
Is Prelude Therapeutics Incorporated stock overvalued by current metricsVolume Spike & Long-Term Investment Growth Plans - DonanımHaber
Will Prelude Therapeutics Incorporated stock pay special dividends2025 Dividend Review & Daily Profit Maximizing Tips - DonanımHaber
Can Prelude Therapeutics Incorporated stock sustain revenue growthJuly 2025 News Drivers & Fast Gain Swing Trade Alerts - DonanımHaber
Why Prelude Therapeutics Incorporated stock attracts global investors2025 Dividend Review & Daily Profit Maximizing Tips - Bölüm Sonu Canavarı
What technical signals suggest for Prelude Therapeutics Incorporated stockJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
Is Prelude Therapeutics Incorporated stock a buy for dividend growthJuly 2025 Closing Moves & Weekly Top Gainers Trade List - Улправда
Prelude Therapeutics Earnings Notes - Trefis
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Prelude Therapeutics divulges new JAK2 inhibitors - BioWorld MedTech
It makes sense and dollars to buy Prelude Therapeutics Inc (PRLD) stock - setenews.com
Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs - MSN
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Prelude Therapeutics (PRLD) Reveals Promising Preclinical Data a - GuruFocus
Prelude Therapeutics Unveils Promising Preclinical Data for JAK2V617F-selective JH2 Inhibitor and mCALR-targeted Degrader Antibody Conjugate at ASH 2025 - Quiver Quantitative
Prelude Therapeutics Presents Data at the 2025 ASH Annual - GlobeNewswire
Prelude Therapeutics (Nasdaq: PRLD) details MPN pipeline at 2025 ASH, eyes 2026 IND - Stock Titan
What insider trading reveals about Prelude Therapeutics Incorporated stockShort Setup & Daily Volume Surge Trade Alerts - Newser
Penny Stocks To Consider In December 2025 - simplywall.st
VIX Spike: How Prelude Therapeutics Incorporated stock compares to industry benchmarksJuly 2025 Decliners & Growth Focused Stock Pick Reports - Bộ Nội Vụ
Growth Report: What dividend safety score for Prelude Therapeutics Incorporated stockJuly 2025 Big Picture & Daily Volume Surge Signals - moha.gov.vn
PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire
This trade activity should not be overlooked: Prelude Therapeutics Inc (PRLD) - Setenews
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus - Zacks Investment Research
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.05%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):